| Expression pattern: |
DN |
| Associated gene: |
hnRNPM, FGF9 mRNA, FGF9 protein |
| Associated microRNA: |
- |
| Biological function: |
protects cardiomyocytes from hypoxia-induced apoptosis; inhibits cardiomyocyte apoptosis; promotes hypoxia-adaption and viability of cardiomyocytes |
| Molecular mechanism: |
circLRP6 2-2 interacts with hnRNPM, translocates into cytoplasm under hypoxia, binds FGF9 mRNA, and acts as a scaffold to promote hnRNPM-mediated FGF9 protein expression; this maintains FGF9 protein level and inhibits hypoxia-induced cardiomyocyte apoptosis. |
| Biological pathway or process: |
apoptosis (inhibits); other pathway/process (promotes) |
| Detected method: |
Q
|
| Validation methods: |
Back-Splice Junction PCR / divergent primers PCR; RNase R Treatment; Sanger Sequencing; RT-qPCR; FISH / smFISH; Nuclear-Cytoplasmic Fractionation; RNA Pull-Down; RIP (RNA Immunoprecipitation); IF (Immunofluorescence); Transfection; TUNEL; Western Blot; In Vivo Animal Model; Bioinformatics Analysis |
| Clinical significance: |
may provide therapeutic targets for coronary heart disease and ischemic myocardial injury |
| Description: |
circLRP6 2-2 is a conserved cardiac circRNA derived from the second exon of LRP6 and is down-regulated in myocardial ischemia and hypoxic cardiomyocytes. It protects cardiomyocytes from hypoxia-induced apoptosis by interacting with hnRNPM, translocating into the cytoplasm under hypoxia, and promoting hnRNPM-mediated FGF9 protein expression through FGF9 mRNA recruitment. The study suggests the circLRP6 2-2/hnRNPM/FGF9 pathway as a potential therapeutic target for coronary heart disease and ischemic myocardial injury. |
| Confidence score: |
0.7909 |